Roche mulling quick fil­ing for a tar­nished Alzheimer’s drug as con­tro­ver­sial Aduhelm OK elec­tri­fies the field — an­a­lyst

It’s in­creas­ing­ly un­clear just how long Bio­gen will have the on­ly ma­jor Alzheimer’s drug on the mar­ket.

Ac­cord­ing to a re­port from Jef­feries, Roche has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.